Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 13/20 | 0.51 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69566 | 0.86 | P4HTM (0.63) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL26436201 | 0.82 | MAPK1 (0.54) | KDM4EALDH1A1RAD52MAPK1L3MBTL1 | |
| SCHEMBL3635773 | 0.79 | P4HTM (0.55) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL1887153 | 0.76 | NAPRT (0.64) | KDM4ERAD52MAPK1L3MBTL1POLB | |
| SCHEMBL3621496 | 0.76 | P4HTM (0.59) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL30828561 | 0.74 | KDM4E (0.65) | P4HTMKDM4EALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL9621696 | 0.74 | P4HTM (0.57) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2501233 | 0.73 | P4HTM (0.49) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL28543859 | 0.73 | P4HTM (0.54) | P4HTM | |
| SCHEMBL22793721 | 0.73 | POLB (0.67) | KDM4EALDH1A1RAD52MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | P4HTM 2494/4885P4HA1 677/4885MIF 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.